ClinicalTrials.gg

Program

AZD7760

A development code.

Its studies are mostly in Staphylococcal Infections · Sepsis, led by AstraZeneca.

Furthest: phase 2, since Dec 23, 20242 company-led studies, 2 open or runningNext primary completion: Mar 8, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca22 open or runningphase 2since Dec 23, 2024Dec 23, 2024Mar 8, 2027phase 2 · NCT06749457
  • Named in AstraZeneca’s own pipeline as AZD7760, phase 2, as of Oct 30, 2026 (source).

Also a collaborator on its studies: parexel.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 23, 2024First study: phase 2 study in Staphylococcal InfectionsFirst studyNCT06749457 · 242 enrolled · United States
  2. May 21, 2026Phase 1 study in Staphylococcus Aureus Bloodstream InfectionNCT07612813 · 18 enrolled · Japan

Ahead

  1. Mar 8, 2027Primary completion: phase 2 study in Staphylococcal InfectionsNCT06749457
  2. Sep 13, 2027Primary completion: phase 1 study in Staphylococcus Aureus Bloodstream InfectionNCT07612813

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07612813Staphylococcus Aureus Bloodstream Infection · Japan1Active, not recruitingSep 13, 202718
NCT06749457Staphylococcal Infections · United States2Active, not recruitingMar 8, 2027242

How it is read

Names in the registry

  • “AZD7760”, 2 entries

Codes read as this program: AZD7760.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.